License revenue 98.1 billion KRW, with sales up 24.8% to 585.2 billion KRW
Yuhan Corporation's Q3 Operating Profit Surges 690%
Yuhan Corporation’s third-quarter operating profit has skyrocketed, primarily due to license revenue from its out-licensed non-small cell lung cancer drug Leclaza.
On the 28th, Yuhan reported that…